查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933897

按劑量、治療方法、包裝類型、通路和患者年齡分類的磷酸伯氨喹片市場，全球預測，2026-2032年

Primaquine Phosphate Tablets Market by Strength, Treatment Regimen, Packaging Type, Distribution Channel, Patient Age - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，磷酸伯氨喹片市值為 1.6839 億美元，預計到 2026 年將成長至 1.7722 億美元，年複合成長率為 5.84%，到 2032 年將達到 2.5056 億美元。

主要市場統計數據
基準年 2025 1.6839億美元
預計年份：2026年 1.7722億美元
預測年份：2032年 2.5056億美元
複合年成長率 (%) 5.84%

本文簡要概述了影響磷酸伯氨喹片使用及相關人員決策流程的當前臨床、監管和供應鏈趨勢。

磷酸伯氨喹仍是清除休眠子、降低復發風險（尤其是在易感人群中）的重要抗瘧藥物。近年來，臨床實踐的改進、安全性監測通訊協定的更新以及分銷模式的轉變，正在改變醫療系統中該藥物的採購和使用方式。因此，相關人員需要整合臨床證據、監管要求和實際操作情況的資訊。

不斷發展的臨床安全通訊協定、採購重點和分銷管道創新如何重塑醫療保健系統中的磷酸伯氨喹片策略

磷酸伯氨喹片市場環境正經歷變革性的變化，這種變化不僅體現在臨床數據上，也體現在政策、採購和分銷管道的演變上。藥物監測技術的進步以及對給藥前安全性篩檢的日益重視，提高了人們對照護現場診斷和整合式診療路徑的期望，迫使醫療服務提供者和生產商在患者篩檢和教育方面進行創新。同時，籌資策略也在進行調整，優先考慮供應的連續性，並更加重視貨源多元化和緊急時應對計畫，以應對地緣政治和物流方面的干擾。

評估2025年美國關稅調整對磷酸伯氨喹片採購韌性、供應商策略和治療連續性的累積影響

2025年關稅上調措施正在對整個醫藥供應鏈產生明顯的連鎖反應，影響依賴進口原料藥和成品藥的採購方式和成本結構。採購團隊正在透過加快供應商資質認證、尋找替代貨源以及審查庫存政策來應對短期價格波動和前置作業時間不確定性。這迫使製造商和經銷商重新評估到岸成本、合約條款和分銷網路，以確保獲得所需產品並遵守不斷變化的貿易規則。

深度細分洞察揭示了分銷管道、劑型、患者人口統計特徵、治療方法偏好和包裝形式如何影響臨床應用和供應優先事項。

細分市場層面的差異對磷酸伯氨喹片的實際商業和臨床決策至關重要，因為它們決定了分銷重點、給藥策略和患者支援需求。不同的分銷管道在營運限制和接觸點方面存在顯著差異。醫院藥局環境優先考慮綜合臨床篩檢和即時給藥，線上藥局管道強調簡化的遠距存取和病患教育，而零售藥局則是慢性病依從性和社區配藥的關鍵樞紐。了解這些分銷管道的特點將有助於指導包裝選擇和所需材料的決策，從而支持安全用藥和提高依從性。

從關鍵的區域觀點審視監管多樣性、製造地和分銷挑戰如何影響全球醫療保健環境中伯氨喹磷酸鹽片劑的獲取。

區域特徵在製定伯氨喹磷酸片的政策、採購和分銷策略方面發揮著至關重要的作用，每個地區都有其獨特的法規結構、臨床實踐和物流挑戰。在美洲，醫療保健生態系統往往強調整合的臨床管道、以控制媒介傳播疾病為目標的公共衛生項目以及影響採購週期和品質保證實踐的既定監管流程。這些特徵促使人們需要可靠的供應鏈和清晰的安全資訊溝通，以支援公共和私營部門的分銷。

主要企業如何透過供應鏈韌性、針對性的產品設計和臨床參與來保持差異化優勢，從而維持伯氨喹療法的可及性和相關人員的信心

在該治療領域運作的公司之間的競爭動態已不再僅僅是商品價格戰；它們越來越重視在品質保證、供應連續性和相關人員參與方面的差異化策略。成功的公司優先考慮健全的供應商選擇框架，在整個價值鏈中保持透明的可追溯性，並投資於符合日益嚴格的藥物監測要求的上市後安全性監測系統。與診斷供應商、物流供應商和區域分銷商建立策略夥伴關係，正逐漸成為確保供應並同時提升對臨床醫生和支付方價值提案的實際有效機制。

製造商和經銷商加強伯氨喹片供應韌性、臨床合作和以患者為中心的商業化的可行優先事項

為保障伯氨喹磷酸片的供應並提升其價值，產業領導者應優先考慮價值鏈強化、臨床合作和以顧客為中心的商業化這三項務實措施。首先，關鍵原料來源多元化並實施端到端可追溯性，將降低單一來源風險，並在出現差異時加快品質調查。同時，加強庫存分析和應急合約的簽訂，以確保在短期供應中斷的情況下仍能保持柔軟性和供給能力。

我們透明的調查方法結合了相關人員訪談、監管審查和跨管道分析，以提供可操作的見解並確定策略轉折點。

本分析透過對關鍵相關人員的訪談、有針對性的監管審查以及對分銷和臨床實踐趨勢的系統評估，全面了解了磷酸伯氨喹片的情況。與臨床醫生、藥品採購負責人、供應鏈經理和監管事務專家的對話是主要的資訊來源，為深入了解安全工作流程、配藥挑戰和採購重點提供了寶貴的見解。此外，本分析也系統性地回顧了與跨境藥品分銷相關的官方監管指南、治療指南和貿易政策趨勢，以補充上述定性觀點。

總之，這項綜合性綜述強調了臨床、監管和營運策略的綜合方法，以維持和最佳化伯氨喹磷酸鹽療法的可及性。

確保伯氨喹磷酸片的穩定供應需要臨床、商業和營運方面的協調努力。諸如安全性篩檢、兒童劑量和治療方案調整等臨床要點必須透過強調多元化、文件記錄和本地化適應性的供應鏈策略來解決。包裝和劑型應根據實際配藥環境進行調整，以減少給藥錯誤並提高用藥依從性。同時，企業必須優先考慮藥物監測和相關人員教育，以維護其醫療服務提供者網路的信任。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 磷酸伯氨喹片市場（按劑量分類）

  • 15mg
  • 26.3mg
  • 7.5mg

9. 依治療方法的磷酸伯氨喹片市場

  • 聯合治療
  • 單藥治療

第10章 依包裝類型分類的磷酸伯氨喹片市場

  • 泡殼包裝
  • 瓶子

第11章 伯氨喹磷酸片市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依病患年齡分類的磷酸伯氨喹片市場

  • 成人
  • 兒童

第13章 伯氨喹磷酸片市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 伯氨喹磷酸鹽片劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國伯氨喹磷酸片市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國磷酸伯氨喹片市場

第17章：中國磷酸伯氨喹片市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actiza Pharmaceutical Pvt. Ltd.
  • AdvaCare Pharma
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Devlife Corporation Private Limited
  • Healthy Life Pharma Pvt. Ltd.
  • Hetero Drugs Limited
  • Intas Pharmaceuticals Limited
  • Ipca Laboratories Limited
  • Johnlee Pharmaceuticals Pvt. Ltd.
  • Lexicare Pharma Pvt. Ltd.
  • Livealth BioPharma Pvt. Ltd.
  • Lupin Limited
  • Marshall Healthcare
  • Medico Remedies Limited
  • Natco Pharma Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-C36616F699B0

The Primaquine Phosphate Tablets Market was valued at USD 168.39 million in 2025 and is projected to grow to USD 177.22 million in 2026, with a CAGR of 5.84%, reaching USD 250.56 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 168.39 million
Estimated Year [2026] USD 177.22 million
Forecast Year [2032] USD 250.56 million
CAGR (%) 5.84%

A concise orientation to current clinical, regulatory, and supply chain dynamics influencing primaquine phosphate tablet use and stakeholder decision pathways

Primaquine phosphate remains an essential agent within antimalarial therapy, particularly for eliminating hypnozoites and reducing relapse risk in vulnerable populations. Recent clinical practice refinements, updated safety monitoring protocols, and evolving distribution patterns have collectively changed how healthcare systems procure and deploy this therapy. Accordingly, stakeholders now require consolidated intelligence that bridges clinical evidence, regulatory expectations, and logistical realities.

This executive summary synthesizes those dimensions and articulates implications for manufacturers, distributors, clinical leaders, and procurement teams. It emphasizes practical considerations such as dosage diversification, pediatric access, and adherence to treatment regimens, while also foregrounding supply chain dependencies and regulatory compliance. The aim is to create a coherent foundation for decision-makers to prioritize interventions, mitigate operational risk, and align commercial strategies with patient-centric outcomes.

How evolving clinical safety protocols, procurement priorities, and channel innovations are reshaping strategy for primaquine phosphate tablets across healthcare systems

The landscape for primaquine phosphate tablets has experienced transformative shifts that extend beyond clinical data to encompass policy, procurement, and channel evolution. Advances in pharmacovigilance and a stronger focus on safety screening prior to administration have raised expectations for point-of-care diagnostics and integrated care pathways, pressuring providers and manufacturers to innovate in patient screening and education. Simultaneously, procurement strategies have adapted to prioritize continuity of supply, with a growing emphasis on supplier diversification and contingency planning to manage geopolitical and logistical disruptions.

Commercial models are also adapting: formulary managers and payers increasingly demand demonstrable value through improved adherence support and packaging innovations that simplify dosing for both adult and pediatric populations. Digital health platforms have begun to influence prescribing and dispensing behaviors, prompting manufacturers to consider packaging and communication strategies that better support remote dispensing and patient follow-up. Taken together, these shifts necessitate a more integrated approach to product development, distribution planning, and stakeholder engagement that aligns clinical efficacy with practical, patient-focused delivery mechanisms.

Assessing the cumulative effects of 2025 United States tariff adjustments on procurement resilience, supplier strategies, and therapeutic continuity for primaquine phosphate tablets

The introduction of increased tariff measures in 2025 has had a discernible ripple effect across pharmaceutical supply chains, influencing procurement practices and cost structures for products dependent on imported active pharmaceutical ingredients and finished doses. Procurement teams have responded by accelerating supplier qualification efforts, seeking alternative sourcing arrangements, and revising inventory policies to hedge against short-term price volatility and lead-time uncertainty. This has compelled manufacturers and distributors to reassess landed costs, contract terms, and distribution footprints to preserve access while maintaining compliance with evolving trade rules.

Clinicians and payers have felt the secondary impacts through tighter negotiation cycles and a renewed emphasis on cost containment in tender environments. In parallel, regulatory bodies and customs authorities have placed enhanced focus on documentation and origin verification, increasing administrative overhead for cross-border shipments. The cumulative effect has been heightened attention to supply-chain transparency, a shift toward regional sourcing where feasible, and a strategic recalibration of inventory buffers and contractual protections to maintain therapeutic continuity for patients reliant on primaquine phosphate therapy.

Deep segmentation insights revealing how distribution channels, dose strengths, patient age groups, regimen choices, and packaging types shape clinical use and supply priorities

Segment-level distinctions are central to practical commercial and clinical decisions for primaquine phosphate tablets because they determine distribution priorities, dosing strategies, and patient support needs. Distribution channels differ markedly in their operational constraints and touchpoints: hospital pharmacy environments prioritize integrated clinical screening and immediate administration, online pharmacy channels emphasize streamlined remote access and patient education, while retail pharmacies serve as critical points for chronic adherence and local dispensing. Understanding these channel dynamics informs decisions about packaging choices and the materials needed to support safe use and adherence.

Product strength variety directly influences prescribing behavior and inventory management. The presence of multiple strengths-including discrete low-dose and higher-dose options-permits prescribers to tailor therapy across both adult and pediatric populations and to accommodate regimen-specific titrations. Patient age segmentation underscores different safety, dosing, and counseling requirements; adult patients generally follow established dosing frameworks, whereas pediatric patients demand age- and weight-appropriate formulations and stronger caregiver education to ensure accurate administration. Treatment regimen segmentation influences clinical positioning and messaging: combination therapy necessitates coordination with partner drugs, pharmacovigilance for drug-drug interactions, and clarity on co-packaging or separate dispensing, whereas monotherapy places greater emphasis on adherence and monitoring for known safety signals. Packaging differences such as blister packs compared with bottles materially affect adherence, stability during distribution, and ease of dosing at the point of care. Blister packs can enhance dose visibility and adherence for segmented regimens, while bottles may offer economies of scale for centralized dispensing or institutional use. Collectively, these segmentation lenses guide product design, supply-chain decisions, and stakeholder communications to better align therapeutic attributes with patient and provider needs.

Critical regional perspectives on regulatory diversity, manufacturing hubs, and distribution challenges shaping access to primaquine phosphate tablets across global healthcare landscapes

Regional dynamics play a decisive role in shaping policy, procurement, and distribution approaches for primaquine phosphate tablets, with each geography presenting distinct regulatory frameworks, clinical practices, and logistical challenges. In the Americas, healthcare ecosystems often emphasize integrated clinical pathways, public health programs targeting vector-borne disease control, and established regulatory processes that influence procurement cycles and quality assurance practices. These characteristics drive demand for reliable supply chains and clear safety communication to support both public and private sector distribution.

Across Europe, the Middle East & Africa, stakeholders confront heterogenous regulatory regimes, variable healthcare infrastructure, and diverse supply-chain resilience profiles. This diversity requires adaptable strategies that span stringent regulatory compliance in some jurisdictions to capacity-building and distribution support in others, particularly where access and cold-chain stability affect rural delivery. The Asia-Pacific region combines high-volume manufacturing capacity with rapidly evolving healthcare delivery models; the region's mix of export-oriented production hubs and dynamic domestic demand necessitates close attention to quality oversight, export compliance, and packaging specifications that match local dispensing practices. Regional prioritization also affects clinical guideline adoption and the emphasis placed on pediatric access, screening protocols, and regimen integration, all of which should inform tailored distribution and stakeholder engagement plans for the therapy across jurisdictions.

How leading companies are differentiating through supply resilience, targeted product design, and clinical engagement to sustain access and stakeholder trust for primaquine therapy

Competitive dynamics among companies active in this therapeutic area increasingly emphasize differentiated approaches to quality assurance, supply continuity, and stakeholder engagement rather than commodity pricing alone. Effective companies prioritize robust supplier qualification frameworks, maintain transparent traceability across the value chain, and invest in post-market safety monitoring systems that align with heightened pharmacovigilance expectations. Strategic partnerships with diagnostic suppliers, logistics providers, and regional distributors have emerged as a practical mechanism to secure supply while enhancing the value proposition for clinicians and payers.

Product-level differentiation is achieved through packaging innovation, patient support programs, and education initiatives that reduce administration errors and support adherence across adult and pediatric populations. Companies that align product offerings with clinical workflows-by developing co-packaging options for combination regimens or by providing dosing aids for pediatric use-tend to secure stronger formulary consideration. In addition, firms that proactively engage with regulatory authorities to streamline documentation and demonstrate commitment to quality tend to experience fewer disruptions in cross-border trade and tenders. Ultimately, resilience in production, clarity in regulatory compliance, and targeted engagement with clinical stakeholders are the defining attributes of companies that successfully manage both operational risk and clinical demand.

Actionable, prioritized steps for manufacturers and distributors to strengthen supply resilience, clinical alignment, and patient-focused commercialization for primaquine tablets

Industry leaders should prioritize a pragmatic blend of supply-chain hardening, clinical alignment, and customer-centric commercialization to protect access and drive value for primaquine phosphate tablets. First, diversify supplier bases for critical inputs and implement end-to-end traceability to reduce single-source risk and expedite quality investigations when discrepancies arise. Pair this with enhanced inventory analytics and contingency contracts that provide both flexibility and capacity during near-term disruptions.

Second, synchronize product design with real-world clinical workflows by developing dosing aids, patient education materials, and packaging options that streamline use across adult and pediatric patients and that support both monotherapy and combination regimens. Third, invest in stronger pharmacovigilance and screening support tools that enable providers to implement safety protocols efficiently, reducing administrative friction and improving patient outcomes. Fourth, align commercial strategies with regional requirements by calibrating regulatory dossiers, packaging specs, and distribution models to local expectations, thereby minimizing clearance delays and improving uptake. Finally, cultivate collaborative partnerships across diagnostics, logistics, and digital-health vendors to create bundled solutions that address clinical screening, adherence monitoring, and remote dispensing, thus enhancing the product's overall value proposition to payers and providers.

A transparent research approach combining stakeholder interviews, regulatory review, and cross-channel analysis to derive practical insights and identify strategic inflection points

This analysis synthesizes primary stakeholder interviews, targeted regulatory reviews, and a structured evaluation of distribution and clinical practice trends to construct a comprehensive perspective on primaquine phosphate tablets. Primary inputs included conversations with clinicians, pharmacy procurement officers, supply-chain managers, and regulatory affairs specialists, which provided nuanced insight into safety workflows, dispensing challenges, and procurement priorities. These qualitative perspectives were complemented by systematic review of public regulatory guidance, treatment guidelines, and trade policy developments relevant to cross-border pharmaceutical movement.

Data were triangulated by comparing stakeholder statements against observed channel behaviors and supply-chain indicators to identify persistent operational themes and strategic inflection points. Particular attention was given to packaging implications for adherence, the operational distinctions across hospital, online, and retail dispensing environments, and the patient-safety implications of dosing and screening practices for adult and pediatric use. Limitations include variability in regional implementation timelines and the evolving nature of trade and regulatory policies; where applicable, recommendations emphasize flexible approaches that can be adapted as conditions change.

Concluding synthesis emphasizing integrated clinical, regulatory, and operational strategies to preserve access and optimize use of primaquine phosphate therapy

Sustaining reliable access to primaquine phosphate tablets requires coordinated action across clinical, commercial, and operational domains. Clinical imperatives such as safety screening, pediatric dosing, and regimen coordination must be matched by supply-chain strategies that emphasize diversification, documentation, and regional adaptability. Packaging and strength options should be aligned with real-world dispensing contexts to reduce dosing errors and support adherence, while companies must prioritize pharmacovigilance and stakeholder education to maintain trust across provider networks.

Taken together, the evidence underscores the importance of integrated planning: treating clinical, regulatory, and logistical factors as interdependent rather than siloed functions. Organizations that implement cross-functional governance, invest in traceable supply chains, and tailor product features to distribution realities will be better positioned to safeguard patient access and respond to policy shifts. The path forward is iterative, requiring ongoing monitoring and adaptable strategies that translate intelligence into operational measures to maintain continuity of care for patients dependent on this therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Primaquine Phosphate Tablets Market, by Strength

  • 8.1. 15 mg
  • 8.2. 26.3 mg
  • 8.3. 7.5 mg

9. Primaquine Phosphate Tablets Market, by Treatment Regimen

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Primaquine Phosphate Tablets Market, by Packaging Type

  • 10.1. Blister Pack
  • 10.2. Bottle

11. Primaquine Phosphate Tablets Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Primaquine Phosphate Tablets Market, by Patient Age

  • 12.1. Adult
  • 12.2. Pediatric

13. Primaquine Phosphate Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Primaquine Phosphate Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Primaquine Phosphate Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Primaquine Phosphate Tablets Market

17. China Primaquine Phosphate Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actiza Pharmaceutical Pvt. Ltd.
  • 18.6. AdvaCare Pharma
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Cipla Limited
  • 18.9. Devlife Corporation Private Limited
  • 18.10. Healthy Life Pharma Pvt. Ltd.
  • 18.11. Hetero Drugs Limited
  • 18.12. Intas Pharmaceuticals Limited
  • 18.13. Ipca Laboratories Limited
  • 18.14. Johnlee Pharmaceuticals Pvt. Ltd.
  • 18.15. Lexicare Pharma Pvt. Ltd.
  • 18.16. Livealth BioPharma Pvt. Ltd.
  • 18.17. Lupin Limited
  • 18.18. Marshall Healthcare
  • 18.19. Medico Remedies Limited
  • 18.20. Natco Pharma Limited
  • 18.21. Sandoz International GmbH
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Taj Pharmaceuticals Limited
  • 18.24. Teva Pharmaceutical Industries Ltd.
  • 18.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 15 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 15 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 15 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 26.3 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 26.3 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 26.3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 7.5 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 7.5 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY 7.5 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BLISTER PACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BLISTER PACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 99. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 101. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 102. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 119. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 120. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA PRIMAQUINE PHOSPHATE TABLETS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)